A second cannabinoid-derivative, called VCE-004.3, also showed potential to enhance anti-inflammatory and anti-fibrotic responses in animal models of scleroderma.
Both EHP-101 and VCE-004.3 are derived from cannabidiol (CBD), one of the natural chemicals extracted from the cannabis plant.
EHP-101 is an oral formulation of VCE-004.8, the original cannabinoid-derivative that was previously shown to alleviate fibrosis when injected in a mouse model of skin fibrosis.
The therapies target and activate two receptors, called peroxisome proliferator-activated receptor gamma (PPAR-γ) and CB2 receptors, increasingly recognized for their potential to prevent inflammation and fibrosis.
In the study “EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis,” published in the journal Biochemical Pharmacology, researchers tested whether oral EHP-101 maintained the same therapeutic properties as VCE-004.8.
Researchers used a